Use of Recombinant Factor VIIa In Gastrointestinal Bleeding in Children with Malignancies: A Case Series

被引：1

作者：

Lee, Jan Hau ^{[1
]}

Ng, Heng Joo ^{[2
]}

Chan, Mei Yoke ^{[1
]}

机构：

[1] KK Womens & Childrens Hosp, Dept Paediat Subspecialties, Singapore, Singapore

[2] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore

来源：

PROCEEDINGS OF SINGAPORE HEALTHCARE | 2010年 / 19卷 / 02期

关键词：

critical illness; factor VIIa; haemorrhage;

D O I：

10.1177/201010581001900211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recombinant factor VIIa (rFVIIa) may be useful in management of severe bleeding in paediatric oncology patients. We described our experience and outcomes in a form of a case series. In all cases, indication was massive gastrointestinal bleeding with haemodynamic instability, persistent thrombocytopenia and coagulopathy despite correction. The range of doses used was 88-102 mcg/kg/dose. Each patient received at least 3 doses. The use of rFVIIa resulted in a reduction in blood product support requirement. rFVIIa was effective in 2 out of 3 patients in stopping the bleeding. There were no drug-related complications. rFVIIa has a critical role to play in the early management of severe bleeding in critically ill paediatric oncology patients.

引用

页码：159 / 162

页数：4

共 10 条

[1] Control of bleeding caused by thrombocytopenia associated with Hematologic malignancy: An audit of the clinical use of recombinant activated factor VII
Brenner, B
Hoffman, R
Balashov, D
Shutluko, E
Culic, S
Nizamoutdinova, E
[J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2005, 11 (04) : 401 - 410
[2] Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding
Conen, Anna
Weisser, Maja
Tsakiris, Dimitrios A.
Siegemund, Martin
[J]. BMC INFECTIOUS DISEASES, 2007, 7 (1)
[3] Pharmacokinetics of recombinant activated factor VII (rFVIIa)
Erhardtsen, E
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) : 385 - 391
[4] Fabritiis P, 2004, HAEMATOLOGICA, V89, P243
[5] Recombinant factor VIIa treatment of bleeding associated with acute renal failure
Moisescu, E
Ardelean, L
Simion, I
Muresan, A
Ciupan, R
[J]. BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (06) : 575 - 577
[6] Revesz T, 1998, THROMB HAEMOSTASIS, V80, P353
[7] The use of recombinant factor VIIa in the treatment of bleeding disorders
Roberts, HR
Monroe, DM
White, GC
[J]. BLOOD, 2004, 104 (13) : 3858 - 3864
[8] Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs adults with haemophilia A
Villar, A
Aronis, S
Morfini, M
Santagostino, E
Auerswald, G
Thomsen, HF
Erhardtsen, E
Giangrande, PLF
[J]. HAEMOPHILIA, 2004, 10 (04) : 352 - 359
[9] Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective
Vincent, Jean-Louis
Rossaint, Rolf
Riou, Bruno
Ozier, Yves
Zideman, David
Spahn, Donat R.
[J]. CRITICAL CARE, 2006, 10 (04)
[10] Off-Label Use of rFVIIa in Children With Excessive Bleeding: A Consecutive Study of 153 Off-Label Uses in 139 Children
Young, Guy
Wicklund, Brian
Neff, Philip
Johnson, Chelsea
Nugent, Diane J.
[J]. PEDIATRIC BLOOD & CANCER, 2009, 53 (02) : 179 - 183

← 1 →